Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SULFAMYLON (mafenide acetate) is a topical antimicrobial cream approved in 1969 for the treatment of burns and wound infections. It works by inhibiting bacterial growth on burn surfaces, reducing infection risk and promoting healing. The drug is indicated for second- and third-degree burns and other traumatic wounds susceptible to bacterial colonization.
Minimal commercial expansion; small team managing legacy product with limited growth opportunity and potential near-term LOE pressure.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
Working on SULFAMYLON offers limited career growth; the product is a mature, niche burn-care legacy brand with minimal hiring and declining commercial momentum. Career advancement is constrained by the product's LOE trajectory and small market footprint; roles are maintenance-oriented rather than growth-oriented.
Worked on SULFAMYLON at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo